 Michelle Haas
Concepts (128)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Latent Tuberculosis | 8 | 2021 | 64 | 3.210 |
Why?
| | Isoniazid | 3 | 2021 | 52 | 0.950 |
Why?
| | Antitubercular Agents | 4 | 2021 | 169 | 0.910 |
Why?
| | Health Systems Plans | 1 | 2020 | 3 | 0.730 |
Why?
| | Tuberculin Test | 1 | 2020 | 32 | 0.720 |
Why?
| | Interferon-gamma Release Tests | 1 | 2020 | 26 | 0.710 |
Why?
| | Tuberculosis | 2 | 2020 | 241 | 0.680 |
Why?
| | Diagnostic Tests, Routine | 1 | 2019 | 87 | 0.640 |
Why?
| | Directly Observed Therapy | 1 | 2018 | 14 | 0.620 |
Why?
| | Mass Screening | 2 | 2020 | 1011 | 0.560 |
Why?
| | Rifampin | 4 | 2021 | 68 | 0.530 |
Why?
| | Mycobacterium Infections | 1 | 2016 | 61 | 0.500 |
Why?
| | Mycobacterium tuberculosis | 1 | 2018 | 268 | 0.500 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2016 | 117 | 0.490 |
Why?
| | Receptors, CXCR5 | 1 | 2014 | 11 | 0.490 |
Why?
| | Lymphoid Tissue | 1 | 2014 | 62 | 0.470 |
Why?
| | Receptors, CXCR4 | 1 | 2014 | 78 | 0.470 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 213 | 0.440 |
Why?
| | HIV-1 | 2 | 2014 | 768 | 0.390 |
Why?
| | Drug Administration Schedule | 3 | 2021 | 718 | 0.330 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2014 | 966 | 0.320 |
Why?
| | Emigrants and Immigrants | 2 | 2020 | 107 | 0.310 |
Why?
| | Drug Therapy, Combination | 2 | 2021 | 954 | 0.280 |
Why?
| | HIV Infections | 2 | 2016 | 2470 | 0.240 |
Why?
| | Anti-Infective Agents | 2 | 2015 | 225 | 0.200 |
Why?
| | Emigration and Immigration | 1 | 2020 | 44 | 0.180 |
Why?
| | Tuberculin | 1 | 2019 | 6 | 0.170 |
Why?
| | Georgia | 1 | 2019 | 62 | 0.170 |
Why?
| | Single-Domain Antibodies | 1 | 2019 | 2 | 0.170 |
Why?
| | Humans | 17 | 2021 | 114937 | 0.160 |
Why?
| | Caliciviridae Infections | 1 | 2019 | 17 | 0.160 |
Why?
| | Norovirus | 1 | 2019 | 23 | 0.160 |
Why?
| | Internal Medicine | 1 | 2020 | 211 | 0.160 |
Why?
| | Female | 12 | 2021 | 59581 | 0.150 |
Why?
| | Retrospective Studies | 5 | 2021 | 12544 | 0.150 |
Why?
| | United States | 4 | 2021 | 12211 | 0.150 |
Why?
| | Skin Diseases, Bacterial | 2 | 2015 | 22 | 0.150 |
Why?
| | Receptors, HIV | 2 | 2014 | 23 | 0.150 |
Why?
| | Drug Monitoring | 1 | 2018 | 184 | 0.140 |
Why?
| | Nitrofurantoin | 1 | 2017 | 7 | 0.140 |
Why?
| | Anti-Infective Agents, Urinary | 1 | 2017 | 13 | 0.140 |
Why?
| | Cystitis | 1 | 2017 | 20 | 0.140 |
Why?
| | Fluoroquinolones | 1 | 2017 | 41 | 0.140 |
Why?
| | Escherichia coli | 2 | 2019 | 722 | 0.140 |
Why?
| | Anti-Bacterial Agents | 2 | 2017 | 1477 | 0.140 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 342 | 0.130 |
Why?
| | Coronavirus Infections | 1 | 2020 | 334 | 0.130 |
Why?
| | Healthcare Disparities | 1 | 2020 | 480 | 0.120 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2015 | 25 | 0.120 |
Why?
| | Male | 10 | 2020 | 55663 | 0.120 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2016 | 112 | 0.120 |
Why?
| | Public Health | 1 | 2019 | 434 | 0.120 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2014 | 39 | 0.120 |
Why?
| | Medication Therapy Management | 1 | 2015 | 67 | 0.110 |
Why?
| | Soft Tissue Infections | 1 | 2014 | 30 | 0.110 |
Why?
| | Adult | 6 | 2021 | 30608 | 0.110 |
Why?
| | Immunophenotyping | 1 | 2014 | 277 | 0.110 |
Why?
| | Global Health | 1 | 2016 | 288 | 0.110 |
Why?
| | Infection Control | 1 | 2015 | 135 | 0.110 |
Why?
| | Quality Improvement | 1 | 2020 | 954 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1215 | 0.110 |
Why?
| | Infant | 3 | 2020 | 7937 | 0.110 |
Why?
| | Drug Prescriptions | 1 | 2015 | 239 | 0.110 |
Why?
| | Pediatrics | 1 | 2020 | 984 | 0.110 |
Why?
| | Cross Infection | 1 | 2015 | 197 | 0.110 |
Why?
| | Anti-HIV Agents | 2 | 2016 | 668 | 0.100 |
Why?
| | Pandemics | 1 | 2020 | 1325 | 0.100 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2011 | 35 | 0.100 |
Why?
| | Receptors, CCR5 | 1 | 2011 | 54 | 0.100 |
Why?
| | Internship and Residency | 1 | 2020 | 944 | 0.090 |
Why?
| | CD4 Antigens | 1 | 2011 | 124 | 0.090 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2016 | 336 | 0.090 |
Why?
| | Middle Aged | 6 | 2021 | 26806 | 0.090 |
Why?
| | HLA-DR Antigens | 1 | 2011 | 220 | 0.090 |
Why?
| | Membrane Glycoproteins | 1 | 2011 | 429 | 0.080 |
Why?
| | T-Lymphocyte Subsets | 1 | 2011 | 384 | 0.080 |
Why?
| | Patient Discharge | 1 | 2015 | 769 | 0.080 |
Why?
| | Health Services Accessibility | 1 | 2015 | 765 | 0.080 |
Why?
| | Child, Preschool | 3 | 2020 | 9086 | 0.080 |
Why?
| | Aged | 3 | 2021 | 19122 | 0.080 |
Why?
| | Gene Expression Profiling | 1 | 2014 | 1523 | 0.080 |
Why?
| | RNA, Viral | 1 | 2011 | 566 | 0.070 |
Why?
| | Hospitalization | 1 | 2015 | 1754 | 0.070 |
Why?
| | Adolescent | 3 | 2020 | 17829 | 0.060 |
Why?
| | Child | 3 | 2020 | 18366 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2020 | 6364 | 0.050 |
Why?
| | Program Evaluation | 2 | 2015 | 824 | 0.040 |
Why?
| | Travel | 1 | 2020 | 121 | 0.040 |
Why?
| | Blood Group Antigens | 1 | 2019 | 14 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2020 | 5035 | 0.040 |
Why?
| | Needs Assessment | 1 | 2020 | 315 | 0.040 |
Why?
| | Capsid | 1 | 2019 | 75 | 0.040 |
Why?
| | Capsid Proteins | 1 | 2019 | 69 | 0.040 |
Why?
| | Colorado | 2 | 2020 | 4091 | 0.040 |
Why?
| | Health Status Disparities | 1 | 2020 | 201 | 0.040 |
Why?
| | Crystallography, X-Ray | 1 | 2019 | 405 | 0.040 |
Why?
| | Epitopes | 1 | 2019 | 436 | 0.030 |
Why?
| | Treatment Failure | 1 | 2018 | 332 | 0.030 |
Why?
| | Cephalosporins | 1 | 2017 | 26 | 0.030 |
Why?
| | Organizational Policy | 1 | 2017 | 68 | 0.030 |
Why?
| | Drug Resistance, Bacterial | 1 | 2017 | 155 | 0.030 |
Why?
| | Binding Sites | 1 | 2019 | 1176 | 0.030 |
Why?
| | Botswana | 1 | 2015 | 7 | 0.030 |
Why?
| | Odds Ratio | 1 | 2018 | 954 | 0.030 |
Why?
| | National Health Programs | 1 | 2015 | 20 | 0.030 |
Why?
| | Population Surveillance | 1 | 2018 | 392 | 0.030 |
Why?
| | Time | 1 | 2015 | 70 | 0.030 |
Why?
| | Drug Utilization Review | 1 | 2015 | 57 | 0.030 |
Why?
| | Drug Resistance, Microbial | 1 | 2015 | 67 | 0.030 |
Why?
| | Inappropriate Prescribing | 1 | 2015 | 52 | 0.030 |
Why?
| | Community-Institutional Relations | 1 | 2015 | 89 | 0.030 |
Why?
| | Hypokalemia | 1 | 2014 | 25 | 0.030 |
Why?
| | Patient Care | 1 | 2015 | 103 | 0.030 |
Why?
| | Safety Management | 1 | 2015 | 109 | 0.030 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2017 | 229 | 0.030 |
Why?
| | Acute Disease | 1 | 2017 | 915 | 0.030 |
Why?
| | Pneumonia, Bacterial | 1 | 2015 | 106 | 0.030 |
Why?
| | Urinary Tract Infections | 1 | 2015 | 133 | 0.030 |
Why?
| | Protein Binding | 1 | 2019 | 1897 | 0.030 |
Why?
| | Community-Acquired Infections | 1 | 2015 | 141 | 0.030 |
Why?
| | Drug Combinations | 1 | 2014 | 286 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2017 | 479 | 0.030 |
Why?
| | Risk Assessment | 1 | 2020 | 2975 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1400 | 0.020 |
Why?
| | Lymph Nodes | 1 | 2011 | 425 | 0.020 |
Why?
| | Young Adult | 1 | 2020 | 10478 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2018 | 9105 | 0.010 |
Why?
| | Risk Factors | 1 | 2014 | 8637 | 0.010 |
Why?
|
|
Haas's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|